All In Biotech

Drug Trial Radar · NCT03590054

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Last checked: Nov 19, 2026Latest source record: Mar 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Aug 20, 2018

Primary completion

Nov 30, 2023

Study completion Nov 30, 2023

Sponsor

Lead sponsor
Rahul AggarwalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Xynomic Pharmaceuticals, Inc.
First posted
Jul 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies the best dose and side effects of abexinostat and how well it works with given together with pembrolizumab in treating participants with microsatellite instability (MSI) solid tumors that have spread to other places in the body. Abexinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving abexinostat and pembrolizumab may work better in treating participants with solid tumors.

Conditions

  • Stage III Cutaneous Melanoma
  • Stage IV Cutaneous Melanoma
  • Locally Advanced Melanoma
  • Locally Advanced Solid Neoplasm
  • Metastatic Head and Neck Squamous Cell Carcinoma
  • Metastatic Malignant Solid Neoplasm
  • Metastatic Melanoma
  • Metastatic Urothelial Carcinoma
  • Non-Small Cell Lung Carcinoma
  • Stage IB Lung Cancer AJCC v7
  • Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
  • Stage III Lung Cancer AJCC v8
  • Stage III Ureter Cancer AJCC v8
  • Stage IIIA Lung Cancer AJCC v8
  • Stage IIIB Lung Cancer AJCC v8
  • Stage IIIC Lung Cancer AJCC v8
  • Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
  • Stage IV Lung Cancer AJCC v8
  • Stage IV Ureter Cancer AJCC v8
  • Stage IVA Lung Cancer AJCC v8
  • Stage IVB Lung Cancer AJCC v8

Interventions

  • AbexinostatDrug

    Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle

  • PembrolizumabBiological

    Given IV on day 1 of every 21 day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximally Tolerated Dose (MTD)Time frame: Up to 21 days
  2. Objective Response Rate (ORR)Time frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.